-
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers
-
Aspen is developing autologous (the patient’s own) induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson’s disease (PD).
-
Dewpoint Therapeutics is the first company to apply the emerging understanding of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions have pathways that are regulated by condensates or arise from the dysfunction of condensates, with programs spanning oncology, neuromuscular, cardiopulmonary, and virology indications.
-
Maze Therapeutics is a biopharmaceutical company applying advanced data science methods in tandem with a robust suite of research and development capabilities to advance a pipeline of novel precision medicines for patients with genetically defined diseases.
-
Shoreline Biosciences is developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and macrophage cellular immunotherapies.
-
ReCode is working to unleash the power of genetic medicine by delivering therapies with our novel LNP platform, which has the potential to reach across a broad spectrum of diseases involving multiple organs and tissues.
-
Immunitas is developing targeted therapeutics for patients with challenging, complex cancers by unlocking human immunology using novel single cell analyses.
-
Sonoma Bio is leveraging the properties of regulatory T cells (Treg) to create living cell therapies that restore the immune system back to its balanced, fully functioning state.
-
Elevation Oncology is working towards a future in which each unique genomic testing result can be matched with a purpose-built precision medicine to bring clarity to every cancer treatment journey.
-
Accent Therapeutics is leading the translation of RNA-modifying protein (RMP) biology into promising new therapies for cancer.
-
Silverback Therapeutics is a private biopharmaceutical company pioneering a new class of immune-modulating drug conjugates.
-
Xilio Therapeutics is focused on advancing highly potent, tumor-selective immunotherapies designed to improve patient outcomes.
-
Harpoon is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that unleash the natural power of the T cells to fight cancer and other diseases.
-
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function.
-
Surrozen is unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway.
-
Morphic Therapeutic is leading the development of a new generation of oral integrin drugs.
-
Fulcrum Therapeutics develops new medicines to deliver a new future for patients and their families by transforming gene regulation in disease.
-
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics.
-
ORIC is dedicated to understanding mechanisms of resistance to cancer treatment, and to discovering and developing therapies to overcome resistance in cancer.
-
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer.
-
Antiva Biosciences, Inc. is a clinical stage biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection.
-
GoCheck Kids is an FDA cleared pediatric vision screener on a smartphone. Parents can now affordably and accurately photoscreen for amblyopia risk factors.
-
D5 Therapeutics is a leading biotechnology company that is discovering novel target and developing innovative medicines in a conceptual frame of syntheticlethality leveraging data-driven platform technology.
-
